Propanc Biopharma Achieves Major Financial Turnaround After Nasdaq Uplisting

Propanc Biopharma has reported a significant financial turnaround following its uplisting to Nasdaq, enhancing its market visibility and opening new investment opportunities. This milestone reflects investor confidence in the company's innovative therapies, particularly in cancer treatment, and marks a pivotal moment for its growth and development in the biopharmaceutical sector.